Morgan Stanley sets Boston Scientific price target at $20

Morgan Stanley researchers have set the price target for shares of Boston Scientific at $20, according to a Mideast Times report.

Advertisement
Carrie Pallardy

Morgan Stanley has a “buy” rating on the stock. Boston Scientific has a 52-week low of $11.10 and a 52-week high of $16.84, according to the report.

More articles on gastroenterology:
Check-Cap IPO unites to trade separately from March 18 onwards
Akron General Partners Physician Group adds Dr. Jeffery Neher
Actavis completes $70.5B Allergan acquisition

Behavioral health’s breaking point: New survey reveals what leaders are prioritizing next

Recommended Live Webinar on Jan 28, 2026 12:00 PM - 1:00 PM CST

Advertisement

Next Up in GI & Endoscopy

  • 5 GI leaders honored in 2025

    In 2025, national gastroenterology and hepatology organizations recognized physicians whose work is advancing digestive disease research, clinical care, education and…

    By: Sophie Eydis

  • The 5 highest-paid gastroenterologists in Miami

    The highest-paid gastroenterologist in Miami earns $979,100 per year, according to Medscape’s salary reporter tool. Here is what the five…

    By: Cameron Cortigiano
Advertisement

Comments are closed.